CN113015730A - 用于治疗与nlrp活性相关的病症的化合物和组合物 - Google Patents

用于治疗与nlrp活性相关的病症的化合物和组合物 Download PDF

Info

Publication number
CN113015730A
CN113015730A CN201980074378.7A CN201980074378A CN113015730A CN 113015730 A CN113015730 A CN 113015730A CN 201980074378 A CN201980074378 A CN 201980074378A CN 113015730 A CN113015730 A CN 113015730A
Authority
CN
China
Prior art keywords
alkyl
compound
hydroxy
aryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980074378.7A
Other languages
English (en)
Chinese (zh)
Inventor
S·古什
J·卡茨
W·鲁斯
H·M·塞德尔
沈东明
S·文卡特拉曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN113015730A publication Critical patent/CN113015730A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980074378.7A 2018-11-13 2019-11-11 用于治疗与nlrp活性相关的病症的化合物和组合物 Pending CN113015730A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862760244P 2018-11-13 2018-11-13
US201862760195P 2018-11-13 2018-11-13
US201862760248P 2018-11-13 2018-11-13
US62/760,248 2018-11-13
US62/760,195 2018-11-13
US62/760,244 2018-11-13
PCT/US2019/060772 WO2020102098A1 (en) 2018-11-13 2019-11-11 Compounds and compositions for treating conditions associated with nlrp activity

Publications (1)

Publication Number Publication Date
CN113015730A true CN113015730A (zh) 2021-06-22

Family

ID=68916530

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980074378.7A Pending CN113015730A (zh) 2018-11-13 2019-11-11 用于治疗与nlrp活性相关的病症的化合物和组合物

Country Status (6)

Country Link
US (1) US12421223B2 (https=)
EP (1) EP3880673B1 (https=)
JP (1) JP2022506891A (https=)
CN (1) CN113015730A (https=)
ES (1) ES2974842T3 (https=)
WO (1) WO2020102098A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649112A1 (en) * 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1300282A (zh) * 1998-05-05 2001-06-20 霍夫曼-拉罗奇有限公司 作为p－38map激酶抑制剂的吡唑衍生物
CN1832928A (zh) * 2003-06-26 2006-09-13 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
WO2008114023A2 (en) * 2007-03-22 2008-09-25 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2017184623A1 (en) * 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
CN107428696A (zh) * 2015-02-16 2017-12-01 昆士兰大学 磺酰脲和相关化合物及其用途
WO2017218617A1 (en) * 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
ZA929699B (en) 1991-12-20 1994-06-14 Lilly Co Eli Sulfonimidamides
US5705398A (en) 1994-03-02 1998-01-06 The Scripps Research Institute Methods for identifying inhibitors of LPS-mediated LBP binding
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US8884006B2 (en) 2011-09-19 2014-11-11 University Of Puerto Rico Small-molecule inhibitors of Rac1 in metastatic breast cancer
TW201439066A (zh) 2012-11-30 2014-10-16 Kyowa Hakko Kirin Co Ltd 含氮雜環化合物
ITMI20131658A1 (it) 2013-10-08 2015-04-09 Getters Spa Combinazione di materiali per dispositivi di rilascio di mercurio e dispositivi contenenti detta combinazione di materiali
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
MX387515B (es) * 2015-10-29 2025-03-18 Merck Sharp & Dohme Llc Inhibidores de factor xia.
FR3046933B1 (fr) * 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
US11447460B2 (en) * 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
CA3021349A1 (en) 2016-04-19 2017-10-26 Innate Tumor Immunity, Inc. Nlrp3 modulators
EP3571187B1 (en) 2017-01-23 2023-11-22 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
ES2988798T3 (es) 2017-07-24 2024-11-21 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
CA3105521A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonimidamide compounds as inhibitors of interleukin-1 activity
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
BR112021003665A2 (pt) 2018-09-13 2021-05-18 Bayer Aktiengesellschaft derivados de heterocicleno como agentes de controle de pragas
EP3911323A4 (en) 2019-01-18 2022-11-16 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
EP3986879B1 (en) 2019-06-21 2024-10-02 AC Immune SA Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1300282A (zh) * 1998-05-05 2001-06-20 霍夫曼-拉罗奇有限公司 作为p－38map激酶抑制剂的吡唑衍生物
CN1832928A (zh) * 2003-06-26 2006-09-13 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
WO2008114023A2 (en) * 2007-03-22 2008-09-25 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CN107428696A (zh) * 2015-02-16 2017-12-01 昆士兰大学 磺酰脲和相关化合物及其用途
WO2017184623A1 (en) * 2016-04-18 2017-10-26 Ifm Therapeutics, Inc Compounds and compositions for treating conditions associated with nlrp activity
WO2017218617A1 (en) * 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SO-YOUNG KIM, ET AL.: ""An Effective Antiviral Approach Targeting Hepatitis B Virus with NJK14047, a Novel and Selective Biphenyl Amide p38 Mitogen-Activated Protein Kinase Inhibitor"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 61, no. 8, 25 July 2017 (2017-07-25), pages 1 - 33 *

Also Published As

Publication number Publication date
WO2020102098A1 (en) 2020-05-22
US12421223B2 (en) 2025-09-23
ES2974842T3 (es) 2024-07-01
EP3880673B1 (en) 2024-01-03
US20230025630A1 (en) 2023-01-26
JP2022506891A (ja) 2022-01-17
EP3880673A1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
JP7654767B2 (ja) Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
CN111094242B (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113166065B (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN112584899A (zh) Nlrp调节剂
CN113056451A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113286784A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
EP3880666B1 (en) Compounds and compositions for treating conditions associated with nlrp activity
CN113316566A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113329998A (zh) 用于治疗与nlrp活性相关的病症的磺酰亚胺酰胺化合物和组合物
CN113227055A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113347970A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113613721A (zh) Nlrp调节剂
CN113015730A (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
TWI914296B (zh) 用於治療與nlrp 活性相關的病症之化合物及組成物
HK40103462A (en) Compounds and compositions for treating conditions associated with nlrp activity
HK40024570A (en) Compounds and compositions for treating conditions associated with nlrp activity
HK40024570B (en) Compounds and compositions for treating conditions associated with nlrp activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210622

WD01 Invention patent application deemed withdrawn after publication